tivozanib hydrochloride · Aveo Pharms · NDA 212904
Fotivda
Earliest generic entry, as listed · earliest of 2 marketed strengths
5 Nov 2039
Blocked by patent: US 11504365. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11504365 | use U-3476 | 5 Nov 2039 |
| US 7166722 | substance, product | 16 Nov 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212904 · 001 · RLD | capsule, oral | EQ 0.89MG BASE | 5 Nov 2039 |
| 212904 · 002 · RLD | capsule, oral | EQ 1.34MG BASE | 5 Nov 2039 |
Expired or delisted (1)
- NCE · 10 Mar 2026